# The Effect of RNS60 on ALS Biomarkers

> **NCT03456882** · PHASE2 · COMPLETED · sponsor: **Mario Negri Institute for Pharmacological Research** · enrollment: 147 (actual)

## Conditions studied

- Amyotrophic Lateral Sclerosis

## Interventions

- **DRUG:** RNS60

## Key facts

- **NCT ID:** NCT03456882
- **Lead sponsor:** Mario Negri Institute for Pharmacological Research
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-30
- **Primary completion:** 2020-11-23
- **Final completion:** 2021-05-30
- **Target enrollment:** 147 (ACTUAL)
- **Last updated:** 2023-04-21

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03456882

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03456882, "The Effect of RNS60 on ALS Biomarkers". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03456882. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*